Overview

Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
To investigate safety, tolerability, maximum tolerated dose of volasertib in Japanese patients with AML
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim